Pathology of the Lung Transplant

Lung and Heart–Lung Transplantation

Volumn , Issue , 2006, Pages 683-722

  Howell, David N ^a   Palmer, Scott M ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249308243     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420019285-34     Document Type: Chapter

References (136)

1. Grossman RF, Frost A, Zamel N, et al. Results of single-lung transplantation for bilateral pulmonary fibrosis. The Toronto Lung Transplant Group. N Engl J Med 1990; 322(11):727–733.
2. Dransfield MT, Garver RI, Weill D. Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients. J Heart Lung Transplant 2004; 23(1):110–114.
3. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996;15(1 Pt 1):1–15.
4. Baz MA, Layish DT, Govert JA, et al. Diagnostic yield of bronchoscopies after isolated lung transplantation. Chest 1996; 110(1):84–88.
5. Valentine VG, Taylor DE, Dhillon GS, et al. Success of lung transplantation without surveillance bronchoscopy. J Heart Lung Transplant 2002; 21(3):319–326.
6. Chakinala MM, Ritter J, Gage BF, et al. Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation. J Heart Lung Transplant 2004; 23(12):1396–1404.
7. Reams BD, McAdams HP, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124(4):1242–1249.
8. Kariyawasam HH, Gyi KM, Hodson ME, et al. Anaemia in lung transplant patient caused by parvovirus B1Thorax 2000; 55(7):619–620.
9. Fields TA, McCall SJ, Reams BD, et al. Pulmonary embolization of microcrystalline cellulose in a lung transplant recipient. J Heart Lung Transplant 2005; 24(5):624–627.
10. de Perrot M, Liu M, Waddell TK, et al. Ischemia–reperfusion-induced lung injury. Am J Respir Crit Care Med 2003; 167(4):490–511.
11. Christie JD, Sager JS, Kimmel SE, et al. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005; 127(1):161–165.
12. Fiser SM, Cope JT, Kron IL, et al. Aerosolized prostacyclin (epoprostenol) as an alternative to inhaled nitric oxide for patients with reperfusion injury after lung transplantation. J Thorac Cardiovasc Surg 2001; 121(5):981–982.
13. Meyers BF, Sundt TM III, Henry S, et al. Selective use of extracorporeal membrane oxygenation is warranted after lung transplantation. J Thorac Cardiovasc Surg 2000; 120(1):20–26.
14. Fisher AJ, Donnelly SC, Hirani N, et al. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am J Respir Crit Care Med 2001; 163(1):259–265.
15. Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001; 71(2):242–246.
16. Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999; 160(5 Pt 1):1611–1616.
17. Husain S, McCurry K, Dauber J, et al. Nocardia infection in lung transplant recipients. J Heart Lung Transplant 2002; 21(3):354–359.
18. Galaria, II, Marcos A, Orloff M, et al. Pulmonary actinomycosis in solid organ transplantation. Transplantation 2003; 75(11):1914–1915.
19. Nichols L, Strollo DC, Kusne S. Legionellosis in a lung transplant recipient obscured by cytomegalovirus infection and Clostridium difficile colitis. Transplant Infect Dis 2002; 4(1):41–45.
20. Palmer SM, Perfect JR, Howell DN, et al. Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. J Heart Lung Transplant 1998; 17(10):1029–1033.
21. Hadjiliadis D, Howell DN, Davis RD, et al. Anastomotic infections in lung transplant recipients. Ann Transplant 2000; 5(3):13–19.
22. Tamm M, Malouf M, Glanville A. Pulmonary scedosporium infection following lung transplantation. Transplant Infect Dis 2001; 3(4):189–194.
23. Liu K, Howell DN, Perfect JR, et al. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol 1998; 109(1):45–54.
24. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001; 33(8):1397–1405.
25. Faul JL, Akindipe OA, Berry GJ, et al. Recurrent Pneumocystis carinii colonization in a heart–lung transplant recipient on long-term trimethoprim– sulfamethoxazole prophylaxis. J Heart Lung Transplant 1999; 18(4):384–387.
26. Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant 2004; 4(8):1219–1226.
27. Caruso JL, Howell DN. Surgical pathology and diagnostic cytopathology of viral infections. In: Lennette EH, Smith TF, eds. Laboratory Diagnosis of Viral Infections. 3rd ed. New York: Marcel Dekker, 1998:21–43.
28. Solans EP, Garrity ER Jr, McCabe M, et al. Early diagnosis of cytomegalovirus pneumonitis in lung transplant patients. Arch Pathol Lab Med 1995; 119(1):33–35.
29. Naber JM, Palmer SM, Howell DN. Cytomegalovirus infection presenting as bronchial polyps in lung transplant recipients. J Heart Lung Transplant 2005; 24(12):2109–2113.
30. Gourishankar S, McDermid JC, Jhangri GS, et al. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004; 4(1):108–115.
31. Shreeniwas R, Schulman LL, Berkmen YM, et al. Opportunistic bronchopulmonary infections after lung transplantation: clinical and radiographic findings. Radiology 1996; 200(2):349–356.
32. Palmer SM Jr, Henshaw NG, Howell DN, et al. Community respiratory viral infection in adult lung transplant recipients. Chest 1998; 113(4):944–950.
33. Matar LD, McAdams HP, Palmer SM, et al. Respiratory viral infections in lung transplant recipients: radiologic findings with clinical correlation. Radiology 1999; 213(3):735–742.
34. Garantziotis S, Howell DN, McAdams HP, et al. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest 2001; 119(4):1277–1280.
35. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol 2003; 25(2):119–140.
36. Baldwin WM III, Kasper EK, Zachary AA, et al. Beyond C4d: other complement-related diagnostic approaches to antibody-mediated rejection. Am J Transplant 2004; 4(3):311–318.
37. Scomik JC, Zander DS, Baz MA, et al. Susceptibility of lung transplants to preformed donor-specific HLA antibodies as detected by flow cytometry. Transplantation 1999; 68(10):1542–1546.
38. Frost AE, Jammal CT, Cagle PT. Hyperacute rejection following lung transplantation. Chest 1996; 110(2):559–562.
39. Choi JK, Kearns J, Palevsky HI, et al. Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings. Am J Respir Crit Care Med 1999; 160(3):1015–1018.
40. Bittner HB, Dunitz J, Hertz M, et al. Hyperacute rejection in single lung transplantation— case report of successful management by means of plasmapheresis and antithymocyte globulin treatment. Transplantation 2001; 71(5):649–651.
41. Christie JD, Bavaria JE, Palevsky HI, et al. Primary graft failure following lung transplantation. Chest 1998; 114(1):51–60.
42. Badesch DB, Zamora M, Fullerton D, et al. Pulmonary capillaritis: a possible histologic form of acute pulmonary allograft rejection. J Heart Lung Transplant 1998; 17(4):415–422.
43. Lau CL, Palmer SM, Posther KE, et al. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 2000; 69(5):1520–1524.
44. Magro CM, Deng A, Pope-Harman A, et al. Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: a hypothesis. Transplantation 2002; 74(9): 1273–1280.
45. Girnita AL, McCurry KR, Iacono AT, et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 2004; 23(10):1135–1141.
46. Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168(6):628–632.
47. Berry GJ, Brunt EM, Chamberlain D, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9(6):593–601.
48. Tazelaar HD. Perivascular inflammation in pulmonary infections: implications for the diagnosis of lung rejection. J Heart Lung Transplant 1991; 10(3):437–441.
49. Sibley RK, Berry GJ, Tazelaar HD, et al. The role of transbronchial biopsies in the management of lung transplant recipients. J Heart Lung Transplant 1993; 12(2):308–324.
50. Yousem SA. Lymphocytic bronchitis/bronchiolitis in lung allograft recipients. Am J Surg Pathol 1993; 17(5):491–496.
51. Ross DJ, Marchevsky A, Kramer M, et al. ‘‘Refractoriness’’ of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografrs. J Heart Lung Transplant 1997; 16(8):832–838.
52. Hasegawa T, Iacono A, Yousem SA. The significance of bronchus-associated lymphoid tissue in human lung transplantation: is there an association with acute and chronic rejection? Transplantation 1999; 67(3):381–385.
53. Yousem SA. Graft eosinophilia in lung transplantation. Hum Pathol 1992; 23(10):1172–1177.
54. Dosanjh AK, Robinson TE, Strauss J, et al. Eosinophil activation in cardiac and pulmonary acute allograft rejection. J Heart Lung Transplant 1998; 17(10):1038.
55. Mogayzel PJ Jr, Yang SC, Wise BV, et al. Eosinophilic infiltrates in a pulmonary allograft: a case and review of the literature. J Heart Lung Transplant 2001; 20(6):692–695.
56. Ohori NP, Iacono AT, Grgurich WF, et al. Significance of acute bronchitis/ bronchiolitis in the lung transplant recipient. Am J Surg Pathol 1994; 18(12): 1192–1204.
57. Lau CL, Palmer SM, Howell DN, et al. Laparoscopic antireflux surgery in the lung transplant population. Surg Endosc 2002; 16(12):1674–1678.
58. Yousem SA, Martin T, Paradis IL, et al. Can immunohistological analysis of transbronchial biopsy specimens predict responder status in early acute rejection of lung allografts? Hum Pathol 1994; 25(5):525–529.
59. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349(2):125–138.
60. Egan JJ. Obliterative bronchiolitis after lung transplantation: a repetitive multiple injury airway disease. Am J Respir Crit Care Med 2004; 170(9): 931–932.
61. Jackson CH, Sharples LD, McNeil K, et al. Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities? J Heart Lung Transplant 2002; 21(6):658–666.
62. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21(3):297–310.
63. Abernathy EC, Hruban RH, Baumgartner WA, et al. The two forms of bronchiolitis obliterans in heart-lung transplant recipients. Hum Pathol 1991; 22(11):1102–1110.
64. Yousem SA, Duncan SR, Griffith BP. Interstitial and airspace granulation tissue reactions in lung transplant recipients. Am J Surg Pathol 1992; 16(9): 877–884.
65. Siddiqui MT, Garrity ER, Husain AN. Bronchiolitis obliterans organizing pneumonia-like reactions: a nonspecific response or an atypical form of rejection or infection in lung allograft recipients? Hum Pathol 1996; 27(7): 714–719.
66. Chaparro C, Chamberlain D, Maurer J, et al. Bronchiolitis obliterans organizing pneumonia (BOOP) in lung transplant recipients. Chest 1996; 110(5): 1150–1154.
67. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 1996; 15(12):1200–1208.
68. Heng D, Sharpies LD, McNeil K, et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998; 17(12):1255–1263.
69. Sharples LD, McNeil K, Stewart S, et al. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002; 21(2):271–281.
70. Hopkins PM, Aboyoun CL, Chhajed PN, et al. Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. Am J Respir Crit Care Med 2004; 170(9):1022–1026.
71. El-Gamel A, Sim E, Hasleton P, et al. Transforming growth factor beta (TGFbeta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999; 18(9):828–837.
72. Luckraz H, Goddard M, McNeil K, et al. Microvascular changes in small airways predispose to obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 2004; 23(5):527–531.
73. Jaramillo A, Smith MA, Phelan D, et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999; 67(8):1155–1161.
74. Smith MA, Sundaresan S, Mohanakumar T, et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 1998; 116(5):812–820.
75. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74(6):799–804.
76. Jaramillo A, Naziruddin B, Zhang L, et al. Activation of human airway epithelial cells by non-HLA antibodies developed after lung transplantation: a potential etiological factor for bronchiolitis obliterans syndrome. Transplantation 2001; 71(7):966–976.
77. Magro CM, Ross P Jr, Kelsey M, et al. Association of humoral immunity and bronchiolitis obliterans syndrome. Am J Transplant 2003; 3(9):1155–1166.
78. Reznik SI, Jaramillo A, Zhang L, et al. Anti-HLA antibody binding to hla class I molecules induces proliferation of airway epithelial cells: a potential mechanism for bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 2000; 119(1):39–45.
79. Jaramillo A, Smith CR, Maruyama T, et al. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 2003; 64(5):521–529.
80. Saunders NA, Smith RJ, Jetten AM. Differential responsiveness of human bronchial epithelial cells, lung carcinoma cells, and bronchial fibroblasts to interferon-gamma in vitro. Am J Respir Cell Mol Biol 1994; 11(2):147–152.
81. Duncan SR, Paradis IL, Yousem SA, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992; 146(6):1419–1425.
82. Husain S, Singh N. Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology. Semin Respir Infect 2002; 17(4):310–314.
83. Tamm M, Aboyoun CL, Chhajed PN, et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004; 170(10):1120–1123.
84. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004; 170(2):181–187.
85. Vilchez RA, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection—myth or reality? Am J Transplant 2003; 3(3):245–249.
86. Billings JL, Hertz MI, Savik K, et al. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002; 21(5):559–566.
87. Gerhardt SG, McDyer JF, Girgis RE, et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003; 168(1):121–125.
88. Grundy JE, Ayles HM, McKeating JA, et al. Enhancement of class I HLA antigen expression by cytomegalovirus: role in amplification of virus infection. J Med Virol 1988; 25(4):483–495.
89. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1(5):398–401.
90. Young LR, Hadjiliadis D, Davis RD, et al. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 2003; 124(5):1689–1693.
91. Hadjiliadis D, Duane Davis R, Steele MP, et al. Gastroesophageal reflux disease in lung transplant recipients. Clin Transplant 2003; 17(4):363–368.
92. Palmer SM, Miralles AP, Howell DN, et al. Gastroesophageal reflux as a reversible cause of allograft dysfunction after long transplantation. Chest 2000; 118(4):1214–1217.
93. Cantu E III, Appel JZ III, Hartwig MG, et al. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004; 78(4):1142–1151; discussion 1142–1151.
94. Fiser SM, Tribble CG, Long SM, et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002; 73(4):1041–1047; discussion 1047–1048.
95. Levine SM, Angel L, Anzueto A, et al. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients. Chest 1999; 116(5):1273–1277.
96. Angel LF, Cai TH, Sako EY, et al. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center. Ann Transplant 2000; 5(3):26–30.
97. Wigle DA, Chaparro C, Humar A, et al. Epstein–Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation 2001; 72(11):1783–1786.
98. Malouf MA, Chhajed PN, Hopkins P, et al. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002; 21(5):547–554.
99. Ramalingam P, Rybicki L, Smith MD, et al. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol 2002; 15(6):647–656.
100. Cohen AH, Sweet SC, Mendeloff E, et al. High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med 2000; 161(4 Pt 1):1252–1255.
101. Gulley ML, Swinnen LJ, Plaisance KT Jr, et al. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 2003; 76(6):959–964.
102. Wood BL, Sabath D, Broudy VC, et al. The recipient origin of posttransplant lymphoproliferative disorders in pulmonary transplant patients. A report of three cases. Cancer 1996; 78(10):2223–2228.
103. Mentzer SJ, Longtine J, Fingeroth J, et al. Immunoblastic lymphoma of donor origin in the allograft after lung transplantation. Transplantation 1996; 61(12): 1720–1725.
104. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85:552–565.
105. Egan JJ, Hazleton PS, Yonan N, et al. Necrotic, ulcerative bronchitis, the presenting feature of lymphoproliferative disease following heart–lung transplantation. Thorax 1995; 50(2):205–207.
106. Legere BM, Saad CP, Mehta AC. Endobronchial post-transplant lymphoproliferative disorder and its management with photodynamic therapy: a case report. J Heart Lung Transplant 2003; 22(4):474–477.
107. Rosendale E, Yousem SA. Discrimination of Epstein–Barr virus-related posttransplant lymphoproliferations from acute rejection in lung allograft recipients. Arch Pathol Lab Med 1995; 119(5):418–423.
108. Nuckols JD, Baron PW, Stenzel TT, et al. The pathology of liver-localized post-transplant lymphoproliferative disease: a report of three cases and a review of the literature. Am J Surg Pathol 2000; 24:733–741.
109. Garver RI Jr, Zorn GL, Wu X, et al. Recurrence of bronchioloalveolar carcinoma in transplanted lungs. N Engl J Med 1999; 340(14):1071–1074.
110. Paloyan EB, Swinnen LJ, Montoya A, et al. Lung transplantation for advanced bronchioloalveolar carcinoma confined to the lungs. Transplantation 2000; 69(11):2446–2448.
111. Zorn GL Jr, McGiffin DC, Young KR Jr, et al. Pulmonary transplantation for advanced bronchioloalveolar carcinoma. J Thorac Cardiovasc Surg 2003; 125(1):45–48.
112. de Perrot M, Chernenko S, Waddell TK, et al. Role of lung transplantation in the treatment of bronchogenic carcinomas for patients with end-stage pulmonary disease. J Clin Oncol 2004; 22(21):4351–4356.
113. de Perrot M, Fischer S, Waddell TK, et al. Management of lung transplant recipients with bronchogenic carcinoma in the native lung. J Heart Lung Transplant 2003; 22(1):87–89.
114. Abrahams NA, Meziane M, Ramalingam P, et al. Incidence of primary neoplasms in explanted lungs: long-term follow-up from 214 lung transplant patients. Transplant Proc 2004; 36(9):2808–2811.
115. Lee P, Minai OA, Mehta AC, et al. Pulmonary nodules in lung transplant recipients: etiology and outcome. Chest 2004; 125(1):165–172.
116. Arcasoy SM, Hersh C, Christie JD, et al. Bronchogenic carcinoma complicating lung transplantation. J Heart Lung Transplant 2001; 20(10):1044–1053.
117. De Soyza AG, Dark JH, Parums DV, et al. Donor-acquired small cell lung cancer following pulmonary transplantation. Chest 2001; 120(3):1030–1031.
118. Knoop C, Jacobovitz D, Antoine M, et al. Donor-transmitted tumors in lung allograft recipients: report on two cases.Transplantation 1994; 57(11):1679–1680.
119. Finkelstein SD,Hasegawa T, Colby T, et al. 11q13 allelic imbalance discriminates pulmonary carcinoids from tumorlets. A microdissection-based genotyping approach useful in clinical practice. Am J Pathol 1999; 155(2):633–640.
120. Ionescu DN, Sasatomi E, Aldeeb D, et al. Pulmonary meningothelial-like nodules: a genotypic comparison with meningiomas. Am J Surg Pathol 2004; 28(2):207–214.
121. Johnson BA, Duncan SR, Ohori NP, et al. Recurrence of sarcoidosis in pulmonary allograft recipients. Am Rev Respir Dis 1993; 148(5):1373–1377.
122. Walker S, Mikhail G, Banner N, et al. Medium term results of lung transplantation for end stage pulmonary sarcoidosis. Thorax 1998; 53(4):281–284.
123. Nunley DR, Hattler B, Keenan RJ, et al. Lung transplantation for end-stage pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16(1):93–100.
124. Burke M, Stewart S, Ashcroft T, et al. Biopsy diagnosis of disease recurrence after transplantation (TX) for pulmonary sarcoidosis: a multicentre study. J Heart Lung Transplant 2001; 20(2):154–155.
125. Slebos DJ, Verschuuren EA, Koeter GH, et al. Bronchoalveolar lavage in a patient with recurrence of sarcoidosis after lung transplantation. J Heart Lung Transplant 2004; 23(8):1010–1013.
126. Nine JS, Yousem SA, Paradis IL, et al. Lymphangioleiomyomatosis: recurrence after lung transplantation. J Heart Lung Transplant 1994; 13(4):714–719.
127. Bittmann I, Rolf B, Amann G, et al. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol 2003; 34(1):95–98.
128. Pechet TT, Meyers BF, Guthrie TJ, et al. Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant 2004; 23(3):301–308.
129. Baz MA, Kussin PS, Van Trigt P, et al. Recurrence of diffuse panbronchiolitis after lung transplantation. Am J Respir Crit Care Med 1995; 151(3 Pt 1): 895–898.
130. Frost AE, Keller CA, Brown RW, et al. Giant cell interstitial pneumonitis. Disease recurrence in the transplanted lung. Am Rev Respir Dis 1993; 148(5):1401–1404.
131. Parker LA, Novotny DB. Recurrent alveolar proteinosis following double lung transplantation. Chest 1997; 111(5):1457–1458.
132. Santamaria F, Brancaccio G, Parenti G, et al. Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance. J Pediatr 2004; 145(2):268–272.
133. Mal H, Guignabert C, Thabut G, et al. Recurrence of pulmonary emphysema in an alpha-1 proteinase inhibitor-deficient lung transplant recipient. Am J Respir Crit Care Med 2004; 170(7):811–814.
134. Sathyapala SA, Gupta NK, Westwood JP, et al. Recurrence of alpha 1-antitrypsin deficiency emphysema on computed tomography (CT) after lung transplantation. J Heart Lung Transplant 2005; 24:S103.
135. Palmer SM Jr, Layish DT, Kussin PS, et al. Lung transplantation for Williams–Campbell syndrome. Chest 1998; 113(2):534–537.
136. Marques LJ, Teschler H, Guzman J, et al. Smoker’s lung transplanted to a nonsmoker. Long-term detection of smoker’s macrophages. Am J Respir Crit Care Med 1997; 156(5):1700–1702.